Imaging Agents

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations
• Disclaimers
• Data Interpretation & Reporting Level
• Quantitative Techniques & Analytics
• Product Definitions and Scope of Study
• A. Contrast Media
  • X-Ray Contrast Media
  • Magnetic Resonance Imaging (MRI) Contrast Media
  • Ultrasound Contrast Media
• B. Diagnostic Radiopharmaceuticals

II. EXECUTIVE SUMMARY

1. Industry Overview

• A Quick Primer On Imaging Agents
• Growth Drivers
• Growth Inhibitors
• Changing Dynamics of Imaging Agents
• Imaging Agents: Significant Growth Ahead
• Table 1: Worldwide Imaging Agents Market (2003): Percentage Breakdown of Value Sales for Leading Imaging Agents-Omnipaque, Cardiolite, Magnevist, Iopamiron, Ultravist, Myoview, Visipaque, Omniscan, FDG and Others (includes corresponding Graph/Chart)
• Rise of Non-Ionizing Imaging Techniques
• Table 2: Medical Diagnostic Procedures Conducted Worldwide for the Year 2003: Breakdown by Imaging Modality Type - X-ray/CT, MRI, Ultrasound and Radiopharmaceuticals (In Millions) (includes corresponding Graph/Chart)
• Fusion Imaging Modalities: Greater Clinical Benefits
• Radiopharmaceuticals-An Exotic Tool
• Nanomaterials Taking the Center Stage
• Gadolinium Coated Nanoparticles- A Promising Imaging Agent
• A Peek Into the Pricing Dynamics
• A Synoptic Overview
• Pros & Cons
• Positive Factors Driving Prices
• Negative Factors Bearing Down on Prices
• Reimbursements
• "Under the Umbrella"
• Europe
• United States

2. Market Trends & Issues

• Falling Prices Turn On the Heat
• X-Ray Contrast Media: Declining Sector
• MRI Contrast Media: Playing at Center Court
• Impact Wielded by Ballooning MRI Practices
• Ultrasound Contrast Media: A Rising Star in the Quadrant
• Fledging Market Battles Teething Challenges
• PET: A Prime Growth Driver for Radiopharmaceuticals
• Nuclear Medicine: A Potential Growth Avenue for Radiopharmaceuticals
• Select Cardiology and Oncology Radiopharmaceuticals

3. Competition

• Market Structure
• Key Market Metrics
• Big Guns in the Emerging MRI Market
• Bayer Schering Pharma AG: A Pioneering Developer of MRI Contrast Agents
• Competitive Scenario - A Recent Past Perspective
• Table 3: Worldwide Imaging Agents Market (2004): Percentage Breakdown of Value Sales for Leading Players- GE Healthcare, Bracco, Tyco Healthcare/Mallinckrodt, Schering, BMS and Others (includes corresponding Graph/Chart)
• Table 4: X-ray Medical Diagnostics Market Worldwide: Percentage Market Share of Leading Players for the Years 2002, 2003, and 2004 - Amersham, Bracco, Tyco/ Mallinckrodt, Inc, Schering, Guerbet and Others (Revenue Share) (includes corresponding Graph/Chart)
• Table 5: MRI Diagnostics Market Worldwide: Percentage Share of Leading Players for the Years 2003 and 2004 - Schering, Amersham, Bracco, and Others (Revenue Share) (includes corresponding Graph/Chart)
• Table 6: Radiopharmaceutical Medical Diagnostics Market Worldwide: Percentage Market Share of Leading Players for the Years 2003 and 2004 - Amersham, Bristol-Myers Squibb, Tyco/ Mallinckrodt, Inc and Others (Revenue Share) (includes corresponding Graph/Chart)

4. Technology Breakthroughs

• Molecular Imaging Agents: The Outer Limits
• On Cards: Hyperpolarized Gases as Contrast Agents
• Imaging Agents Make a Welcome Impact in the Field of Alzheimer' s Disease
• Technetium-99m: A Breakthrough Contrast Agent for CNS Imaging
• A New Imaging Agent for Radiopharmaceutical Scans
• Multi-Modal Image Registration: Combating Contrast Medium Inconsistencies
• Saline Flushes To Help Ensure Accurate Delivery of Contrast Agents

5. Product Overview

• Contrast Agents
• Contrast Media: How Do They Function?
• Where Are They Used...?
• Evolution of Contrast Media: A Profile
• Bismuth Nitrate: Beginning of Contrast Agents
• Imaging Agents: Significant Developments in the Last Fifty Years
• Schering Develops First Intravenous Contrast Agent
• MRI: Creating a New Era for Contrast Agents
• A Peek into the Finer Points of Differences Among Contrast Media
• Viscosity
• Osmolality
• Chemotoxicity
• Second Generation Non-Ionic Contrast Agents: An Introduction
• Choice of the Contrast Medium: A Weighty Decision
• Factors affecting choice of Imaging Agents
• Taxonomy
• Types of Contrast Media
• X-Ray Contrast Medium
• First Generation High Osmolar Contrast Media
• Second Generation Low Osmolar Contrast Media or LOCM
• Table 7: Comparative Analysis of Structure of Non-ionic and ionic X-ray Contrast Media
• MRI Contrast Medium
• Role of Contrast Enhancement in MR Angiography (MRA)
• MRI Contrast Agents for the Liver
• Paramagnetic extracellular contrast agents
• Hepatobiliary Gadolinium Chelates
• Superparamagnetic Iron Oxide Particles
• Ultrasound Contrast Medium
• Ultrasonographic Contrast Media: What Are They?
• Ultrasound Contrast Enhancement in Cardiology
• Functionalities of Vascular Ultrasound Contrast Agents
• Diagnostic Radiopharmaceuticals
• Key Radioactive Isotopes used as Diagnostic Radiopharmaceuticals
• A Delineate of Diagnostic Radiopharmaceuticals
• Diagnostic Radiopharmaceuticals: A Technical Run-Through
• Applications

6. A Segmental Review

• Contrast Media
• Popular Brands of Contrast Agents Available Worldwide
• A Peek into Select Imaging Agents Under Clinical Trials Worldwide
• X-ray Contrast Media
• Market Scenario
• MRI Contrast Media
• Market Scenario
• Ultrasound Contrast Media
• Market Overview
• Competitive Scenario
• Diagnostic Radiopharmaceuticals
• Market Overview
• Immunoconjugates
• Market Overview
• Competitive Scenario

7. Technology Dynamics

• Proprietary Technologies Making Significant In-Roads
• Advanced Magnetics' Proprietary Colloidal Superparamagnetic Particle Technology
• Enzon' s Single Chain Antigen-Binding Technology
• Immunomedics' Antibody Technology
• First Generation
• Second Generation
• Third Generation
• NeoRx' s "Painting the Target" Technology
• Stage - I
• Stage - II
• Stage - III
• Gas Encapsulation Technology for Ultrasound Contrast Media
• Pharmacyclics' Texaphyrin Technology
• Regulatory Bodies
• Ultrasound Contrast Agents Are Drugs, Not Devices - Rules US FDA
• Entry Barriers
• Research Driven Markets
• Highly Competitive Market
• Economies of Scale
• Substitutes in Agents Manufacturing
• New X-ray Diagnostic Agents
• Amide-based Macrocyclic Ligands - Potential MRI Agents
• Gadolinium (III) Complexes - Potential MRI Contrast Agents
• Metal-Containing Compounds Act As Potential Contrast Agents
• Therapeutic Applications
• Diagnostic Applications
• Magnetic Gels as Potential MRI Contrast Agents
• PFCs as Diagnostic Contrast Agents

8. Product Launches

• Bayer to Unleash Radiology Management System
• Bayer to Unveil Pre-Filled Contrast-Medium Cartridges for MRI
• Insight Agents to Launch Generic Contrast Media Solutions In Europe
• Researchers Develop First Biocompatible MRI Contrast Agent
• Signalomics and Invitrogen Collaborate to Develop Nanocrystal Reagents
• Schering AG Collaborates with Stanford University to Develop Molecular Imaging Agent
• Schering and Avid to Develop Diagnostic Imaging Agents
• US National Institutes of Health Develops two PET Imaging Agents
• Bracco Diagnostics Canada Introduces MRI Contrast Agent MultiHance
• JBCPL Launches Magnilek Contrast Agent
• Mallinckrodt Launches NeutroSpec™
• Schering AG' s Primovist™ Approved in Sweden
• Isovue - A Non-ionic Monomeric X-Ray Contrast Agent from Bracco Diagnostics
• Schering Strengthens Position with MS-325
• Berlex Launches MRI Contrast Agent
• Amersham Health Introduces Omnipaque
• Boston Scientific Corp Launches Galaxy System
• Syncor International Launches F-18 FDG

9. Recent Industry Activity

• Bristol-Myers Squibb Medical Imaging Adopts New Identity, Lantheus Medical Imaging
• Cytogen Corporation to Merge Business with EUSA Pharma Inc
• Bracco Group Acquires E-Z-EM
• EPIX Pharmaceuticals to Resubmit New Drug Application (NDA) for Vasovist
• Bayer Schering, FutureChem Ink Licensing Deal
• NuView Radio Pharmaceuticals Inks Agreement for Non- Invasive Imaging Agent
• Advanced Magnetics Inc Changes Name to AMAG Pharmaceuticals
• Bracco Diagnostics Inks Agreement with HealthTrust Purchasing Group
• Bracco Diagnostics Offers MRI Products to HealthTrust Purchasing Group
• Bayer HealthCare Offers MRI Contrast Agent to HealthTrust
• Bayer HealthCare Extends Contract with Premier
• Bayer HealthCare Sets Off US Operations
• Tyco Healthcare Renamed to Covidien Ltd
• Covidien Offers Imaging Solutions to MedAssets Supply Chain Systems
• Siemens, M.D. Anderson Cancer Center Set up Research Centre
• Bayer, Berlex Merge Operations
• AION Diagnostics Forays Pre-Clinical Imaging Agent Market
• ART Acquires Alerion Biomedical
• EPIX to Merge with Predix
• Fujifilm Acquires Stake in Daiichi Radioisotope Laboratories
• Bracco Diagnostics Inks Agreement with Amerinet Vasovist receives Green Signal in Australia
• AION Diagnostics Develops BioSilicon TM
• Sonazoid Receives Import Approval
• Schering AG Divests Radiopharmaceutical Business to Ion Beam Applications and Institut National des Radioelements
• Vasovist Receives European Approval
• Albany Molecular Research Renews Supply Agreement with GE Healthcare
• QuantRx Biomedical Corp. Acquires Stake in FluoroPharma
• Palatin Technologies Withdraws NeutroSpec Imaging Agent
• Diosynth Bags Contract to Produce Imaging Agent
• GE Healthcare Signs Marketing Agreement with PhotoCure
• DRAXIMAGE Receives the Green Signal in Europe
• Daiichi and Sankyo Sign a Merger Deal
• Bristol Myers and Imcor Pharmaceutical Forge Cross- Licensing Agreement
• Kereos and Dow to Develop Unique Targeted Imaging Agents
• Bristol-Myers and Kereos to Collaborate on Molecular Imaging Agents
• GE Acquires Amersham PLC
• Photogen Technologies Acquires Imagent®
• Dow and Kereos Collaborate
• IBC Pharmaceuticals and Schering AG Collaborate on Cancer Research
• Schering Purchases CIS Bio International
• Imaging Diagnostic Systems to Collaborate with Schering
• Mallinckrodt Signs Distribution Agreement with Proxima Therapeutics
• Immunomedics Signs Marketing Agreement with Teva-Tuteur
• DRAXIS Increases BrachySeed Production
• DRAXIMAGE Obtains FDA Approval for Manufacturing Lyophilized Products
• Nycomed Amersham Acquires Bruker' s TOMOJET
• DuPont Acquires Caribbean-PharmaLogic Radiopharmacies
• Bristol-Myers Squibb Company Acquires DuPont Pharmaceuticals
• Alliance Pharmaceutical Completes Acquisition of Molecular Biosystems
• GE Medical Acquires Coincidence Technologies
• Tyco International Acquires Mallinckrodt
• Zydus Cadila Acquires 27.72 % Stake in German Remedies
• Schering Acquires Manufacturing Rights of MS-325 from EPIX Medical
• Zydus Cadila Acquires Five Brands from Asta Medica
• AxCell BioSciences Forms Joint Venture with Institute for Systems Biology
• Syncor Signs Purchasing Agreements with HSCA
• Syncor and InSource Health Services Sign Agreement
• DRAXIS Signs Agreement with BTG for INFECTON
• Peregrine Pharmaceuticals and Paul Scherrer Institute Expand R&D Agreement
• Syncor and Broadlane Ink Agreement
• Syncor and Catholic Healthcare West Extend Agreement
• MedImmune and Targesome Sign R&D Agreement
• Vital Images Inks an Agreement with E-Z-EM Inc
• TriPath Imaging and MDS Ink Agreement
• North American Scientific Forges Strategic Relationship with Certus International
• Mediaworks Launches RadiologyWeb
• Nycomed Amersham Extends Supply Contract with Novation
• Advanced Magnetics Receives Approval for Feridex
• Targesome Receives NCI Support for Developing Novel Diagnostic Imaging Agents
• Bracco Acquires Product Lines and Intellectual Property of Resolution Pharmaceuticals
• Guerbet Acquires Oxilan, an X-Ray Contrast Agent from Cook Imaging
• Nycomed Amersham Imaging Associates with Global Healthcare Exchange
• Nycomed Amersham and D-Pharm Ally to Develop New Imaging Agents
• Bracco Group Forges Strategic Alliance with Dyax Corp
• DRAXIS Signs Agreement with Cytogen Corp
• CV Therapeutics and Fujisawa Healthcare Sign Collaboration Agreement
• Comprehensive Medical Imaging Signs Agreement with US Diagnostic
• Syncor International and GE Medical Systems Sign Strategic Agreement
• Guilford Pharmaceuticals Licenses Dopascan to MAP Medical Technologies
• Cytogen and Advanced Magnetics Sign Agreements
• Amersham Sells Nycomed Pharma Subsidiary
• Amersham Renames its Businesses
• Nycomed Amersham Obtains Approval from FDA for MYOVIEW
• Schering Obtains Approval for Cancer Imaging Agent
• Datscan Receives European Union Marketing Authorization

10. Focus on Select Players

• AMAG Pharmaceuticals Inc (USA)
• Amersham Plc (UK)
• Bayer Schering Pharma AG (Germany)
• Bayer HealthCare Pharmaceuticals (US)
• Bracco Group (Italy)
• E-Z-EM Inc. (USA)
• Covidien (USA)
• Cytogen Corp. (USA)
• Daiichi Sankyo Company Limited (Japan)
• Eisai Co., Ltd (Japan)
• EPIX Pharmaceutical Inc. (USA)
• Guerbet Group (France)
• Lantheus Medical Imaging (USA)

11. Global Market Perspective

• Table 8: World Recent Past, Current & Future Analysis for Imaging Agents by Geographic Region- US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 9: World Long-term Projections for Imaging Agents by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 10: World 10-Year Perspective for Imaging Agents by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 11: World Recent Past, Current & Future Analysis for Contrast Media by Geographic Region- US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 12: World Long-term Projections for Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 13: World 10-Year Perspective for Contrast Media by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 14: World Recent Past, Current & Future Analysis for Contrast Media by Product Segment - X-Ray, MRI and Ultrasound Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 15: World Long-term Projections for Contrast Media by Product Segment - X-Ray, MRI and Ultrasound Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 16: World 10-Year Perspective for Contrast Media by Product Segment - Percentage Breakdown of Dollar Sales for X-Ray, MRI and Ultrasound Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 17: World Recent Past, Current & Future Analysis for X-Ray Contrast Media by Geographic Region- US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 18: World Long-term Projections for X-Ray Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 19: World 10-Year Perspective for X-Ray Contrast Media by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 20: World Recent Past, Current & Future Analysis for MRI Contrast Media by Geographic Region- US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 21: World Long-term Projections for MRI Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia- Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 22: World 10-Year Perspective for MRI Contrast Media by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 23: World Recent Past, Current & Future Analysis for Ultrasound Contrast Media by Geographic Region- US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 24: World Long-term Projections for Ultrasound Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 25: World 10-Year Perspective for Ultrasound Contrast Media by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 26: World Recent Past, Current & Future Analysis for Diagnostic Radiopharmaceuticals by Geographic Region- US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 27: World Long-term Projections for Diagnostic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 28: World 10-Year Perspective for Diagnostic Radiopharmaceuticals by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

III. MARKET

1. The United States

• A. Market Analysis
  • Outlook
  • Growth Stimulants
  • Medical Imaging: Changing the Healthcare Landscape
  • Dynamics of Pricing
  • Table 29: Hospital Purchases by GPOs in the United States - Percentage Breakdown by Type for the Year 2002 (includes corresponding Graph/Chart)
  • Reimbursements Issues
  • Medicare
  • Magnetic Resonance Imaging
  • Table 30: Medicare Reimbursements for Brain MRI Procedures for the Year 2006
  • Table 31: Medicare Reimbursements for Breast MRI Procedures for the Year 2006
  • Regulatory Environment
  • Provisions Regarding Off-Label Usage of Contrast Media
  • Contrast Media
  • X-ray Contrast Media
  • MRI Contrast Media
  • Market Scenario
  • Managed Care Vs MRI Technology Diffusion
  • Ultrasound Contrast Media Market
  • Diagnostic Radiopharmaceuticals
  • Market Scenario
  • Availability of Isotopes: A Tough Challenge
  • Select Players
  • Strategic Corporate Developments
  • Product Launches
• B. Market Analytics
  • Table 32: US Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 33: US Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 34: US Historic Review for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1995 through 1999 (includes corresponding Graph/Chart)
  • Table 35: US 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

2. Canada

• A. Market Analysis
  • Outlook
  • Diagnostic Equipment Market
  • LOCM Products Approved in Canada
  • Select Player
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 36: Canadian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 37: Canadian Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 38: Canadian 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

3. Japan

• A. Market Analysis
  • Outlook
  • Reimbursement Issues
  • Select Players
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 39: Japanese Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 40: Japanese Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 41: Japanese 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4. Europe

• A. Market Analysis
  • Outlook
  • Trends
  • Reimbursement
  • Distribution Structure
  • Direct Sales
  • License Agreements
  • Distribution Agreements
  • A Price Sensitive Market
  • Table 42: European Contrast Media Market (2005): Average Cost of Contrast Media Per Imaging Procedure
  • Table 43: Product Price of Select Contrast Agents in Europe by Company
  • Macro Market Environment
  • Germany
  • France
  • United Kingdom
  • Spain & Italy
  • Scandinavia
  • Strategic Corporate Developments
  • Product Launch
• B. Market Analytics
  • Table 44: European Recent Past, Current & Future Analysis for Imaging Agents by Geographic Region - France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 45: European Long-term Projections for Imaging Agents by Geographic Region - France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 46: European 10-Year Perspective for Imaging Agents by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
  • Table 47: European Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 48: European Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 49: European 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4a. France

• A. Market Analysis
  • Outlook
  • Growth Stimulants
  • Contrast Media
  • Major Player
  • Strategic Corporate Developments in the Recent Past
• B. Market Analytics
  • Table 50: French Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radio-pharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 51: French Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 52: French 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4b. Germany

• A. Market Analysis
  • Outlook
  • Major Player
  • Strategic Corporate Developments
  • Product Launches
• B. Market Analytics
  • Table 53: German Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 54: German Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 55: German 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4c. The United Kingdom

• A. Market Analysis
  • Outlook
  • Major Player
  • Strategic Corporate Developments in the Recent Past
• B. Market Analytics
  • Table 56: UK Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 57: UK Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 58: UK 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4d. Italy

• A. Market Analysis
  • Outlook
  • Major Player
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 59: Italian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 60: Italian Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 61: Italian 10-Year Perspective for Imaging Agents by Product Segment-Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4e. Spain

• Market Analysis
• Table 62: Spanish Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radio- pharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 63: Spanish Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 64: Spanish 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4f. Russia

• Market Analysis
• Table 65: Russian Recent Past, Current & Future Analysis for Imaging Agents by product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 66: Russian Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 67: Russian 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4g. Rest of Europe

• A. Market Analysis
  • Outlook
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 68: Rest of Europe Recent Past, Current & Future Analysis for Imaging Agents by Product Segment-Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 69: Rest of Europe Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 70: Rest of Europe 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

5. Asia-Pacific

• A. Market Analysis
  • Outlook
  • PET Imaging-An Overview
  • ANSTO: Leading the Radiopharmaceuticals Market
  • Strategic Corporate Developments
  • Product Launch
• B. Market Analytics
  • Table 71: Asia-Pacific Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 72: Asia-Pacific Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 73: Asia-Pacific 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

6. The Middle East

• Market Analysis
• Table 74: Middle East Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 75: Middle East Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 76: Middle East 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

7. Latin America

• Market Analysis
• Table 77: Latin American Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 78: Latin America Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 79: Latin American 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE